Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.Journal of the American Academy of Dermatology|August 29, 2024
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvementMark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled TrialsLinda F Stein Gold, Michael T Jarratt, Alicia D Bucko, et al.Dermatology and Therapy|November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.The New England Journal of Medicine|April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque PsoriasisKim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.Dermatology and Therapy|May 17, 2026
Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful TrialNina Magnolo, Jennifer Soung, John Frew, et al.JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.Pageof 2